Measuring PI3K activation: Clinicopathologic, immunohistochemical, and RNA expression analysis in prostate cancer

Neil E. Martin, Travis Gerke, Jennifer A. Sinnott, Edward C. Stack, Ove Andrén, Swen-Olof Andersson, Jan-Erik Johansson, Michelangelo Fiorentino, Stephen Finn, Giuseppe Fedele, Meir Stampfer, Philip W. Kantoff, Lorelei A. Mucci, Massimo Loda


Assessing the extent of PI3K pathway activity in cancer is vital to predicting sensitivity to PI3K-targeting drugs, but the best biomarker of PI3K pathway activity in archival tumor specimens is unclear. Here, PI3K pathway activation was assessed, in clinical tissue from 1,021 men with prostate cancers, using multiple pathway nodes that include PTEN, phosphorylated AKT (pAKT), phosphorylated ribosomal protein S6 (pS6), and stathmin. Based on these markers, a 9-point score of PI3K activation was created using the combined intensity of the 4-markers and analyzed its association with proliferation (Ki67), apoptosis (TUNEL), and androgen receptor (AR) status, as well as pathologic features and cancer-specific outcomes. In addition, the PI3K activation score was compared with mRNA expression profiling data for a large subset of men. Interestingly, those tumors with higher PI3K activation scores also had higher Gleason grade (P = 0.006), increased AR (r = 0.37; P < 0.001) and Ki67 (r = 0.24; P < 0.001), and decreased TUNEL (r = -0.12; P = 0.003). Although the PI3K activation score was not associated with an increased risk of lethal outcome, a significant interaction between lethal outcome, Gleason and high PI3K score (P = 0.03) was observed. Finally, enrichment of PI3K-specific pathways was found in the mRNA expression patterns differentiating the low and high PI3K activation scores; thus, the 4-marker IHC score of PI3K pathway activity correlates with features of PI3K activation.

Published In Molecular Cancer Research
Date Oct 1, 2015
DOI 10.1158/1541-7786.MCR-14-0569


Martin NE, Gerke TA, Sinnott JA, Stack EC, Andrén O, Andersson S, Johansson J, Fiorentino M, Finn S, Fedele G, Stampfer MJ, Kantoff PW, Mucci LA, Loda MF. Measuring PI3K activation: Clinicopathologic, immunohistochemical, and RNA expression analysis in prostate cancer. Mol Cancer Res 2015; 13(10): 1431--1440. PMID: 26124442. PMCID: PMC4618038.